Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Lixte Biotechnology (LIXT)

Lixte Biotechnology Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LIXT
DateTimeSourceHeadlineSymbolCompany
06/06/202413:30GlobeNewswire Inc.Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune SystemNASDAQ:LIXTLixte Biotechnology Holdings Inc
03/06/202413:30GlobeNewswire Inc.LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical OfficerNASDAQ:LIXTLixte Biotechnology Holdings Inc
08/05/202414:25GlobeNewswire Inc.LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”NASDAQ:LIXTLixte Biotechnology Holdings Inc
24/04/202420:25AllPennyStocks.comMixed Shelf Filing Gives Micro Cap Delayed BoostNASDAQ:LIXTLixte Biotechnology Holdings Inc
27/03/202419:35AllPennyStocks.comBiotech Steals The Show Following Pre-Clinical Data AnnouncementNASDAQ:LIXTLixte Biotechnology Holdings Inc
27/03/202412:30GlobeNewswire Inc.NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESNASDAQ:LIXTLixte Biotechnology Holdings Inc
21/03/202412:30GlobeNewswire Inc.LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer TreatmentsNASDAQ:LIXTLixte Biotechnology Holdings Inc
27/02/202421:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
27/02/202413:30GlobeNewswire Inc.Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer ResearchNASDAQ:LIXTLixte Biotechnology Holdings Inc
26/02/202415:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
26/02/202413:30GlobeNewswire Inc.LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCINASDAQ:LIXTLixte Biotechnology Holdings Inc
29/01/202413:30GlobeNewswire Inc.First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma TrialNASDAQ:LIXTLixte Biotechnology Holdings Inc
28/11/202322:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
13/11/202319:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
13/11/202313:30GlobeNewswire Inc.LIXTE Biotechnology Provides Update on Clinical Progress and Expanding CollaborationsNASDAQ:LIXTLixte Biotechnology Holdings Inc
09/11/202322:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIXTLixte Biotechnology Holdings Inc
17/10/202322:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
16/10/202319:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIXTLixte Biotechnology Holdings Inc
16/10/202313:30GlobeNewswire Inc.LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand CollaborationNASDAQ:LIXTLixte Biotechnology Holdings Inc
10/10/202320:55Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:LIXTLixte Biotechnology Holdings Inc
10/10/202320:47Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:LIXTLixte Biotechnology Holdings Inc
09/10/202313:30GlobeNewswire Inc.LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. KovachNASDAQ:LIXTLixte Biotechnology Holdings Inc
06/10/202301:39Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:LIXTLixte Biotechnology Holdings Inc
06/10/202301:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIXTLixte Biotechnology Holdings Inc
04/10/202323:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIXTLixte Biotechnology Holdings Inc
29/09/202321:05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:LIXTLixte Biotechnology Holdings Inc
27/09/202311:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
27/09/202311:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIXTLixte Biotechnology Holdings Inc
26/09/202313:30GlobeNewswire Inc.LIXTE Appoints Bas van der Baan as President and Chief Executive OfficerNASDAQ:LIXTLixte Biotechnology Holdings Inc
20/09/202316:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:LIXT

Your Recent History

Delayed Upgrade Clock